Press Releases Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-10 EDT			5-day change	1st Jan Change
2.15 ^USD	+3.12%		+6.44%	+22.16%

05-08	Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	Top Premarket Gainers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	05-08	AQ
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting	04-11	AQ
Indaptus Therapeutics : April 2024 April 2024 Investor Presentation	04-07	PU
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference	03-28	AQ
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting	03-25	AQ
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024	03-18	AQ
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	03-13	AQ
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort	03-04	AQ
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference	02-15	AQ
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	02-08	AQ
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology	01-04	AQ
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	11-06	AQ
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study	11-06	AQ
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting	23-10-31	AQ
Indaptus Therapeutics to Present at the LD Micro Main Event XVI	23-09-27	AQ
Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023	23-09-26	AQ
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20	23-09-19	AQ
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-14	AQ
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20	23-08-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Press Releases

Filters